Georges Thiry becomes COO at BioNet-Asia

He takes up the role early next year at the pertussis vaccine developer

BioNet-Asia, a Thai company focused on vaccine discovery and supply, has appointed Georges Thiry as COO. He takes up the role early in 2015 and replaces Dario Cresci who established BioNet's manufacturing site and completed the upscale of the company's first key vaccines.

Cresci will remain on the company's Advisory Committee.

Thiry is currently Director of the Dengue Vaccine Initiative and Chairman of the Product Development Team for the Tuberculosis Vaccine Initiative. He has spent the last 30 years in vaccine research and development. He was formerly Director of Projects at GlaxoSmithKline Biologicals before joining several public institutions such as the International AIDS Vaccine Initiative, PATH and the International Vaccine Institute. At PATH, a global health organisation, he also led several public private partnerships for the development of new rotavirus vaccines in developing countries.

For nearly ten years, BioNet has been working on the development of a new recombinant pertussis (RP) vaccine. All licensed acellular pertussis (aP) vaccines currently use a detoxified pertussis toxin which is denatured by the use of chemicals.

The BioNet RP vaccine contains a genetically-engineered non-toxic pertussis toxin, which could potentially be the solution to the re-emergence of pertussis (whooping cough) in many developed countries.

You may also like

Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Manufacturing

Servier opens new €86m biologics production facility in Loiret, France

The company's Bio-S facility will be responsible for the production of biological medicines stemming from its R&D pipeline for preclinical and clinical studies
Manufacturing

Leybold launches Duradry vacuum pump for harsh processes

Advanced technology designed for reliability and efficiency
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Subscribe now